利索-全球专利检索

  1. Login
  2. Sign Up

Search Results

16 records (took 0.012 seconds)

    CO-DIFFERENTIATION AND ACTIVATION OF MONOCYTES FROM ALLOGENEIC DONORS TO PROVIDE PRO-INFLAMMATORY DENDRITIC CELLS
    6.
    发明公开
    CO-DIFFERENTIATION AND ACTIVATION OF MONOCYTES FROM ALLOGENEIC DONORS TO PROVIDE PRO-INFLAMMATORY DENDRITIC CELLS 有权
    CO-分化和从同种异体供体的单核细胞的活化，以提供促炎症树突状细胞

    公开(公告)号：EP2913394A1

    公开(公告)日：2015-09-02

    申请号：EP15161369.2

    申请日：2013-12-18

    Applicant: Immunicum AB

    Inventor： Karlsson-Parra, Alex ,  Andersson, Bengt

    IPC: C12N5/0784 ,  C12N5/0786

    CPC classification number: C12N5/0639 ,  A61K35/15 ,  C12N2500/40 ,  C12N2501/22 ,  C12N2501/2304 ,  C12N2501/24 ,  C12N2506/115

    Abstract: Disclosed is a method of producing pro-inflammatory dendritic cells (DCs) originating from at two different, allogeneic donors. In the method, a mixture of allogeneic leukocytes, which allogeneic leukocytes have been obtained from at least two different, allogeneic donors is provided. Subsequently, allogeneic monocytes are isolated from the mixture of allogeneic leukocytes. Thereafter, non-exhausted immature DCs are generated from said isolated allogeneic monocytes, which subsequently are activated to obtain pro-inflammatory DCs.

    Abstract translation: 公开的是从在两个不同的，同种异体供体生产促炎树突细胞（DC）发起的方法。 在该方法中，提供了同种异体白细胞，其中同种异体白细胞havebeen从至少两个不同的，同种异体供体获得的混合物。 随后，同种异体的单核细胞是从同种异体白细胞的混合物中分离。 那里之后，从所述被生成的非耗尽未成熟的DCs分离同种异体的单核细胞，其随后被激活以获得促炎性的DCs。

    NEW METHOD AND COMPOSITION FOR PRODUCING A CELLULAR ALLOGENEIC VACCINE
    8.
    发明授权
    NEW METHOD AND COMPOSITION FOR PRODUCING A CELLULAR ALLOGENEIC VACCINE 有权
    用于生产蜂窝异基因疫苗的新方法和组合物

    公开(公告)号：EP1509244B1

    公开(公告)日：2011-07-27

    申请号：EP03730977.0

    申请日：2003-06-05

    Applicant: Immunicum AB

    Inventor： KARLSSON-PARRA, Alex ,  WALLGREN, AnnaCarin ,  ANDERSSON, Bengt

    IPC: A61K39/00 ,  C12N1/00

    CPC classification number: A61K39/0011 ,  A61K2039/5154 ,  C12N5/0645 ,  C12N2501/599 ,  C12N2501/70 ,  Y02A50/472

    Abstract: A method for the production of a cellular allogeneic vaccine, which is based upon an allogeneic APC, includes the following steps: a) isolation of an APC from a subject or providing an APC already established and/or isolated from a myeloid leukemia cell line, and b) modifying the APC with an antigen using any of the following methods: pulsing, transfection, infection or fusion; c) treatment using an agent capable of removing sialic acid on cell surfaces; and optionally d) culturing the APC in a suitable medium, an allogeneic vaccine obtainable by the above method, a composition comprising the vaccine and a pharmaceutically acceptable carrier and therapeutic use of the vaccine or the composition.

Patent Agency Ranking